连续性肾替代治疗:真的不需要高容量血液滤过吗?  

Do we really not need high-volume hemofiltration?

作　　者：谭若铭[1] 瞿洪平[1] 

机构地区：[1]上海交通大学医学院附属瑞金医院重症医学科,200025

出　　处：《中华重症医学电子杂志》2017年第1期65-68,共4页Chinese Journal Of Critical Care & Intensive Care Medicine(Electronic Edition)

摘　　要：高容量血液滤过(high-volume hemofiltration,HVHF)通过清除炎症因子、减轻炎症反应、减轻脏器功能损伤,从而改善患者血流动力学状态、脏器功能及临床预后。HVHF已成为脓毒症、脓毒症休克及其他全身炎症反应综合征的辅助治疗手段之一。然而,目前关于HVHF的临床相关研究仍存在争议,尚缺乏随机对照临床试验(randomized clinical trial,RCT)研究证实其可改善危重患者生存率。在临床实际应用中仍需临床医师对其进行谨慎解读及全面评估利弊。High-volume hemofiltration （HVHF） can improve hemodynamics, organ dysfunction and outcome through removing inflammatory factors in critically ill patients. HVHF has been one of the adjuvant therapies for systemic inflammatory response syndrome such as sepsis and septic shock. However, there is still lack of randomized clinical trial （RCT） evidence about whether HVHF can improve survival or not in critically ill patients. Therefore, clinicians should carefully interpret the results of current clinical studies and balance the benefits and harms of HVHF when selecting the mode and dose of renal replacement therapy.

关 键 词：高容量血液滤过 全身炎症反应综合征 脓毒症 连续性肾替代治疗 

分 类 号：R459.5[医药卫生—治疗学]